Aberrant KEAP1 methylation was also reported in 53% of colorectal cancer, head and neck cancer tissues (29.3%) and prostate cancer cells as the main mechanism of epigenetic silencing of KEAP1 expression with clinical prognostic significance [19,32,33]. This evidence concerns the gene KEAP1 and prostate cancer.